Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 14, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on May 13, 2025, acting through corporate stockbroker Citigroup Global Markets Limited.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share buybacks. No revenue, profit, cash flow, or debt metrics are provided in this specific document.
- Shares Purchased (May 13, 2025): 783,700 ordinary shares
- Price Range (GBp): 1,355.50p (Low) to 1,411.50p (High)
- Volume-Weighted Average Price (GBp): 1,376.15p
- Trading Venue: London Stock Exchange (XLON)
- Treasury Shares Held: 210,524,142 (post-transaction)
- Shares in Issue (excluding Treasury): 4,104,732,246
- Total Voting Rights: 4,104,732,246
Material Changes and Program Status
The purchase was conducted pursuant to a non-discretionary agreement entered into on February 24, 2025. Since the inception of this agreement, GSK has purchased an aggregate of 41,453,839 ordinary shares. The shares acquired on May 13 are held as Treasury shares.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, management commentary on operations, or specific risk factors beyond a standard cautionary statement. GSK notes that forward-looking statements are subject to risks and uncertainties described in its 2024 Annual Report on Form 20-F and Q1 2025 Results.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback program initiated on February 24, 2025.
- Confirm the total number of voting rights (4,104,732,246) for disclosure threshold calculations under FCA rules.
- Review the Q1 2025 Results and 2024 Form 20-F for context on the company's overall liquidity and capital allocation strategy.